Upon completing my fellowship in June 2014, I joined the NYU Langone faculty and served as study physician for CTN-0051 (extended-release naltrexone versus buprenorphine opioid treatment, U10 DA013035), and as co-investigator for a National Institutes of Health (NIH)-funded trial, extended-release naltrexone versus oral naltrexone for the treatment of alcohol use disorders in primary care (R01AA020836-01). I was also awarded an NYU Langone Clinical and Translational Science Institute pilot award ($35,000) and a NIH National Center for Advancing Translational Sciences grant ($262,708) to develop mobile health tools supporting patient linkage and retention in buprenorphine treatment. Subsequently, I was awarded a NIH National Institute on Drug Abuse K23 Career Development Award ($969,069) to complete intensive training and clinical studies on leveraging low-cost and ubiquitous technologies to improve access to effective pharmacotherapies for substance use disorders in primary care.
180 Madison Avenue
New York, NY 10016
Journal of substance abuse treatment. 2021 Oct 01; 129:?-?
Addictive behaviors reports. 2021 Jun ; 13:100329
Journal of substance abuse treatment. 2021 May ; 124:108292